EarningsQ2 2026 Earnings Report
MX:JNJ Q2 2026 EPS Results
Actual EPS$52.09
Consensus EPS$51.28
Beat/MissBeat by +$0.81
One Year Ago EPS$49.76
MX:JNJ Q2 2026 Revenue Results
Actual Revenue$454.75B
Expected Revenue$450.18B
Beat/MissBeat by +$4.57B
YoY Revenue Growth+6.64%
Earnings Announcement Details
QuarterQ2 2026
Date07/15/2026
TimeBefore Open
Conference CallWednesday, July 15, 2026
MX:JNJ Upcoming Earnings
Johnson & Johnson's next earnings date is estimated for October 13, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:JNJ Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call was broadly positive: the company reported solid top‑line growth, strong performance from a broad set of Innovative Medicine launches (many products delivering high double‑digit growth), successful new product launches (ICOTYDE, INLEXZO), raised guidance for full‑year sales and EPS, and improved operating margin expectations. Headwinds exist — notably STELARA's steep decline, MedTech pressure in cardiovascular/Abiomed, regional inventory impacts (China), higher other expenses and a higher GAAP tax rate — but management characterized these as addressable and emphasized diversified, multi‑product strength, cash flow recovery, and upcoming pipeline and regulatory catalysts.Company Guidance
Strong Q2 Revenue and Raised Full‑Year Guidance
Worldwide sales of $25.3 billion; operational sales growth of 5.6% in Q2. Company raised full‑year 2026 operational sales growth guidance to 6.5%–7.1% (midpoint $100.6B) and reported sales growth guidance to 7.0%–7.6% (midpoint $101.1B).
Innovative Medicine Momentum
Innovative Medicine sales $16.4 billion, up 6.8% operationally despite an approximate 760 basis point headwind from STELARA; excluding STELARA the business grew double digits. Adjusted income before tax margin for Innovative Medicine remains strong (42.5%).
Multiple High‑Growth Products
Major brands delivered outsized growth: TREMFYA +71.0%; CARVYKTI +47.7%; TECVAYLI +56.1% (sequential +29.2% worldwide, U.S. sequential +46.2%); TALVEY +62.6%; RYBREVANT +61.6%; DARZALEX grew ~17.6% to >$4 billion in sales.
Successful New Launches — ICOTYDE & INLEXZO
ICOTYDE: >18,000 prescriptions, ~11,000 patients initiated therapy, ~6,000 unique prescribers (50% advanced practice), >50% commercial coverage within 90 days; INLEXZO: nearly 1 in 3 eligible patients started therapy, new patient insertions +75% quarter‑over‑quarter, sales more than doubled Q2 vs Q1 (company beat consensus).
MedTech Product Strengths and Innovation
MedTech sales $8.9 billion, up 3.6% operationally. Notable product momentum: VARIPULSE (pulsed field ablation) >85,000 AFib patients treated; Shockwave grew +14.7%; vision growth +5.6% driven by premium IOLs and ACUVUE contact lenses; progress toward robotics (OTTAVA) and CE mark for ETHICON 4000 stapler.
Profitability, EPS and Cash Flow Progress
Adjusted net earnings $7.1 billion and adjusted diluted EPS $2.90 (adjusted EPS +4.7% YoY). Updated full‑year adjusted operational EPS guidance $11.50–$11.65 (midpoint growth ~7.3% YoY). YTD free cash flow improved to ~$8.7 billion and on track for full‑year outlook approaching $21 billion; cash & marketable securities ~$21 billion.
Pipeline and M&A Catalysts
Pipeline catalysts expected in H2 (e.g., FDA decision for IMAAVY; multiple data readouts including TECVAYLI+TALVEY, pasritamig, J&J 6143, INLEXZO and ICOTYDE indications). Announced planned acquisition of Firefly Bio to expand oncology platform; continued strategic R&D investments.
Operating Leverage and Margin Outlook Improved
Company now expects ~75 basis points improvement in adjusted pre‑tax operating margin for 2026 (up from >50 bps prior expectation), supported by operating efficiencies and tariff recoupment assumptions.
MX:JNJ Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed